Article Information
History
- August 6, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Gagandeep Singh1,2,
- Anass Abbad1,2,
- Giulio Kleiner1,2,
- Komal Srivastava1,2,
- Charles Gleason1,2,
- PARIS Study Group1,2,
- Juan Manuel Carreño1,2,
- Viviana Simon1,2,3,4,5 and
- Florian Krammer1,2,3,*
- 1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 2Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 3Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 4Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 5The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ↵*To whom correspondence should be addressed: florian.krammer{at}mssm.edu
Posted August 06, 2023.
The post-COVID-19 population has a high prevalence of crossreactive antibodies to spikes from all Orthocoronavirinae genera
